COMPASS Pathways (CMPS) 25th Annual Needham Virtual Healthcare Conference summary

Clinical development and regulatory progress

• Phase III program for COMP360 in treatment-resistant depression shows rapid and durable efficacy, with 25–40% of patients achieving clinically meaningful responses and effects lasting up to 26 weeks after one or two doses.

• Safety profile is favorable, with transient adverse effects resolving within 24–48 hours and no concerning imbalances in suicidality observed by the DSMB.

• NDA submission is underway, with completion expected in early Q3 after 26-week data from the second study; priority review anticipated.

• Commercial readiness is targeted for the end of the year, pending regulatory milestones.

Commercial strategy and infrastructure

• Existing SPRAVATO infrastructure enables rapid integration of COMP360, as sites certified for SPRAVATO can easily add COMP360.

• New CPT codes specific to psychedelic treatments are approved and live, ensuring optimal reimbursement for providers based on treatment duration.

• Buy and bill will be enabled, with 30–40% of SPRAVATO volume currently using this model; pricing will be informed by final dosing data.

• Focus will be on high-prescribing, multi-hour treatment sites for initial launch, leveraging strategic collaborations and field medical teams.

Training, education, and site activation

• Many providers are already trained in foundational psychedelic care; additional COMP360-specific training will be brief and accessible, with grants provided to training organizations.

• Metrics tracked include infrastructure readiness, REMS certification, site activation, prescriber adoption, patient numbers, and payer coverage.

• State-level rescheduling post-DEA is critical for launch, with efforts to minimize delays and ensure rapid access.